The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro

Cancer Investigation

Volumn 26, Issue 7, 2008, Pages 718-724

  Chen, Xiaojun ^a   Xiao, Wei ^a   Qu, Xun ^a   Zhou, Shengyu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Dalteparin; Low molecular weight heparin; Lung adenocarcinoma; p21WAF1; p27 KIP1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING;

ADENOCARCINOMA; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS;

EID: 48249094625     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801935631     Document Type: Article

References (45)

1. Klerk, C.P.; Smorenburg, S.M.; Otten, H.M.; et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005, 23, 2130-2135.
2. Kakkar, A.K.; Levine, M.N.; Kadziola, Z.; et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22, 1944-1948.
3. Altinbas, M.; Coskun, H.S.; Er, O.; et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004, 2(8), 1266-1271.
4. Icli, F.; Akbulut, H.; Utkan, G.; et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007, 95(6), 507-512.
5. Clowes, A.W.; Karnovsky, M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265(5595), 625-626.
6. Guyton, J.R.; Rosenberg, R.D.; Clowes, A.W.; et al. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980, 46(5), 625-634.
7. Horiuchi, A.; Nikaido, T.; Ya-Li, Z.; et al. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Mol Hum Reprod 1999, 5(2), 139-145.
8. Coffey, A.K.; Karnovsky M.J. Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 1985, 120(2), 248-255.
9. Johnson, P.R.; Armour, C.L.; Carey, D.; et al. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am J Physiol 1995, 269(4 Pt 1), L514-519
10. Erduran, E.; Tekelioǧlu, Y.; Gedik, Y.; et al. Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Am J Hemato 1999, 61(2), 90-93.
11. Margarita, S.B.; Abel, S.A.; Miguel, A.P. Cell cycle deregulation in B-cell lymphomas. Blood 2003, 101(4), 1220-1235.
12. Massaque, J.; Polyak, K. Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 1995, 5(1), 91-96.
13. Slingerland, J.; Pagano, M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000, 183(1), 10-17.
14. Zou, X.; Ray, D.; Aziyu, A.; et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002, 16(22), 2923-2934.
15. Yu, L.; Quinn, D.A.; Garg, H.G.; et al. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005, 97(9), 937-945.
16. Collen, A.; Smorenburg, S.M.; Peters, E.; et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000, 60(21), 6196-6200.
17. Nasir, F.A.; Patel, H.K.; Scully M.F. The low molecular weight heparin dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumor model. Blood 2003, 102(3), Abstract.
18. Borsig, L.; Wong, R.; Feramisco, J.; et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001, 98(6), 3352-3357
19. Ludwig, R.J.; Boehme, B.; Podda, M.; et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004, 64(8), 2743-2750.
20. Koenig, A.; Norgard-Sumnicht, K.; Linhardt, R.; et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998, 101(4), 877-889.
21. Christopherson, K.W.; Campbell, J.J.; Travers, J.B.; et al. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 2002, 302(1), 290-295.
22. Smorenburg, S.M.; Van, N.C.J.F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001, 53(1), 93-105.
23. Ishii, T.; Fujishiro, M.; Masudav M.; et al. Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells. Eur Respir J 2004, 23(5), 665-670.
24. Gottlieb, T.M.; Oren, M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287(2-3), 77-l02.
25. Helin, K.; Lees, J.A.; Vidal, M.; et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992, 70(2), 337-350.
26. Brehm, A.; Miska, E.A.; McCance, D.J.; et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (Lond) 1998, 391(6667), 597-601.
27. Sherr, C.J.; Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13(12), 1501-1512.
28. Stavenow, L.; Lindblad, B.; Xu, C.B.; Unfractionated heparin and low molecular weight heparin do not inhibit the growth of proliferating human arterial smooth muscle cells in culture. Eur J Vasc Endovasc Surg 1995, 10(2), 215-219.
29. Vannucchi, S.; Pasquali, F.; Chiarugi, V.P.; et al. Inhibition of BC3H-1 cell growth by heparin is related to decreased mitogenic signaling. Biochem Biophys Res Commun 1990, 170(1), 89-95.
30. Yu, M.K.; Lee, D.Y.; Kim, Y.S.; et al. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res 2007, 24(4), 705-714.
31. Lincet, H.; Poulain, L.; Remy, J.S.; et al. The p21 (cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000, 161(1), 17-26.
32. Shibata, M.A.; Yoshidome, K.; Shibata, E.; et al. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 2001, 8(1), 23-35.
33. Fotedar, R.; Brickner, H.; Saadatmandi, N.; et al. Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 1999, 18(24), 3652-3658.
34. Supriatno; Harada, K.; Hoque, M.O.; et al. Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 2002, 38(7), 730-736.
35. Katayose, Y.; Kim, M.; Rakkar, A.N.; et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997, 57(24), 5441-5445.
36. Berry, D.; Lynn, D.M.; Sasisekharan, R.; et al. Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol 2004, 11(4), 487-498.
37. Erduran, E.; Deger, O.; Albayrak, D.; et al. In vitro investigation of the apoptotic effect of heparin on lymphoblasts by using flow cytometric DNA analysis and fluorometric caspase-3 and -8 activities. DNA Cell Biol 2007, 26(11), 803-808.
38. Erduran, E.; Tekelioglu, Y.; Gedik, Y.; et al. In vitro determination of the apoptotic effect of heparin on lymphoblasts using DNA analysis and measurements of Fas and Bcl-2 proteins by flow cytometry. Pediatr Hematol Oncol 2004, 21(5), 383-391.
39. Gartel, A.L.; Tyner, A.L. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999, 246(2), 280-289.
40. Sheaff, R.J.; Singer, J.D.; Swanger, J.; et al. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000, 5(2), 403-410.
41. Touitou, R.; Richardson, J.; Bose, S.; et al. A degradation signal located in the C-terminus of p21WAF1/ CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. Embo J 2001, 20(10), 2367-2375.
42. Maki, C.G.; Howley, P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997, 17(1), 355-363.
43. Carrano, A.C.; Eytan, E.; Hershko, A.; et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol 1999, 1(4), 193-199.
44. Fareed, J.; Leong, W.L.; Hoppensteadt, D.A.; et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004, 30(6), 703-713.
45. Deepa, P.R.; Varalakshmi, P. The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity. Eur J Pharmacol 2003, 478(2-3), 199-205.